Fast Track Designation Long
In plain terms
When the FDA grants a Fast-Track or Priority Review designation, we go long the sponsor for the next 2-3 months.
How it works
FDA expedited-pathway designations (Fast-Track, Breakthrough Therapy, Priority Review) compress the review timeline and signal the regulator's unmet-need view; Anderson-Zhang 2010 document abnormal trading volume and positive excess daily stock returns for sponsors around 100+ fast-track designations (1998-2004), strongest for small, pre-revenue, low-institutional-ownership firms.
Data dependencies
- Daily prices
Adjusted-close OHLCV for every US-listed ticker; primary price feed.
- Fda adcomm
A data feed this strategy reads, refreshed on its normal schedule.
Expected edge
- Reported return
- Positive announcement-window abnormal returns and volume (100+ fast-track designations, 1998-2004); the prior +5% event-day / +8% over-60d figures were unsupported by the previously cited BMJ 2017 paper and are removed.
- Tested over
- T+1 to T+60d
Anderson-Zhang 2010: positive designation-announcement abnormal returns and abnormal volume, strongest for small pre-revenue, low-institutional-ownership sponsors; no single headline CAR reported.
Example tickers where this is likely to fire
Illustrative only, the signal fires based on the live data, not a fixed list.
Related families
FDA AdComm + PDUFA target dates are ±15% binary catalysts.
When a drug company publicly posts the results of a late-stage (Phase III) trial, bet that its stock drifts down over the following weeks, and hold for about 2 to 8 weeks. The trade waits until the results are actually public before taking any position.
Explore Fast Track Designation Long on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.